Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Rating of "Moderate Buy" by Analysts

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) have received an average recommendation of "Moderate Buy" from the five research firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $17.25.

ENTA has been the topic of a number of research reports. HC Wainwright restated a "buy" rating and issued a $18.00 price objective on shares of Enanta Pharmaceuticals in a report on Tuesday, February 11th. StockNews.com upgraded shares of Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Wednesday, February 19th. Finally, JMP Securities reiterated a "market outperform" rating and issued a $21.00 price objective on shares of Enanta Pharmaceuticals in a report on Tuesday, February 11th.

Insider Transactions at Enanta Pharmaceuticals

In other Enanta Pharmaceuticals news, CEO Jay R. Luly bought 45,000 shares of the firm's stock in a transaction that occurred on Wednesday, February 12th. The stock was purchased at an average price of $5.69 per share, for a total transaction of $256,050.00. Following the purchase, the chief executive officer now directly owns 846,638 shares in the company, valued at $4,817,370.22. This trade represents a 5.61 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 13.89% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of ENTA. Tower Research Capital LLC TRC raised its stake in Enanta Pharmaceuticals by 46.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 7,202 shares of the biotechnology company's stock valued at $41,000 after purchasing an additional 2,274 shares during the last quarter. AlphaQuest LLC raised its position in shares of Enanta Pharmaceuticals by 16.4% during the fourth quarter. AlphaQuest LLC now owns 22,260 shares of the biotechnology company's stock valued at $128,000 after buying an additional 3,137 shares during the last quarter. Invesco Ltd. lifted its stake in shares of Enanta Pharmaceuticals by 7.3% in the fourth quarter. Invesco Ltd. now owns 46,614 shares of the biotechnology company's stock valued at $268,000 after buying an additional 3,186 shares during the period. American Century Companies Inc. grew its position in Enanta Pharmaceuticals by 10.5% during the fourth quarter. American Century Companies Inc. now owns 36,962 shares of the biotechnology company's stock worth $213,000 after buying an additional 3,501 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. acquired a new position in Enanta Pharmaceuticals in the 4th quarter valued at approximately $26,000. 94.99% of the stock is currently owned by institutional investors and hedge funds.

Enanta Pharmaceuticals Stock Up 0.9 %

Shares of ENTA traded up $0.04 during trading hours on Friday, reaching $4.50. The company's stock had a trading volume of 383,093 shares, compared to its average volume of 281,080. The firm has a market cap of $96.00 million, a price-to-earnings ratio of -0.91 and a beta of 0.69. The company has a 50 day moving average of $6.33 and a two-hundred day moving average of $7.76. Enanta Pharmaceuticals has a 1-year low of $4.10 and a 1-year high of $17.24.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last issued its earnings results on Monday, February 10th. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative net margin of 157.57% and a negative return on equity of 75.53%. As a group, analysts forecast that Enanta Pharmaceuticals will post -4.65 EPS for the current fiscal year.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.